Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Q1 2025 Earnings Call Transcript May 7, 2025 Vishay Intertechnology, Inc. reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Good day, and thank ...